Group 1 - The core viewpoint of the news is that Prasis (Shanghai) Pharmaceutical Technology Development Co., Ltd. has seen a stock price increase of 5.15%, reaching 48.16 CNY per share, with a total market capitalization of 3.805 billion CNY as of September 30 [1] - The company was established on February 22, 2013, and went public on May 17, 2022, focusing on technology development, transfer, consulting, and services in the pharmaceutical sector, with 100% of its revenue coming from services [1] - The trading volume for Prasis on the reporting date was 75.4268 million CNY, with a turnover rate of 2.13% [1] Group 2 - Among the top ten circulating shareholders of Prasis, a fund under Rongtong Fund has increased its holdings by 100,000 shares to a total of 1 million shares, representing 1.33% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) has achieved a year-to-date return of 17.3% and a one-year return of 23.7%, ranking 4996 out of 8167 and 4660 out of 8010 in its category, respectively [2] - The fund was established on December 25, 2014, and has a current size of 2.074 billion CNY, with a cumulative return of 183.4% since inception [2]
普蕊斯股价涨5.15%，融通基金旗下1只基金位居十大流通股东，持有100万股浮盈赚取236万元